
SPRB Stock Forecast & Price Target
SPRB Analyst Ratings
Bulls say
Spruce Biosciences is poised for success based on strong physician feedback and its innovative product candidate, TA-ERT, which addresses a significant unmet medical need in MPS IIIB. With similar biomarker and clinical data to Avalayah, recent accelerated approval for a rare disorder, Spruce has adequate line of sight for its BLA submission in 4Q26 and a potential first-mover advantage in this white space market, with exclusive IP through 2037-2038 and market data supports $300M+ peak sales. Additionally, entering the market with a strong balance sheet, Spruce is well-positioned to become a cash flow generator for future pipeline development.
Bears say
Spruce Biosciences is a late-stage biopharmaceutical company focused on developing and commercializing therapies aimed at rare endocrine disorders. The company's lead candidate, TA-ERT, has shown promising results in clinical trials, but there are still uncertainties regarding regulatory approval and commercialization. With a limited pipeline and potential financial risks, the outlook for Spruce Biosciences may be negative.
This aggregate rating is based on analysts' research of Spruce Biosciences Inc and is not a guaranteed prediction by Public.com or investment advice.
SPRB Analyst Forecast & Price Prediction
Start investing in SPRB
Order type
Buy in
Order amount
Est. shares
0 shares